Gut Microbiome Composition Offers Insights for Diagnosis and Intervention of Early Alzheimer’s Disease
Even at the earliest (preclinical) stage of AD, when the affected individuals remain cognitively intact with no apparent neurodegeneration, changes in the brain are already occurring. These changes include the accumulation of proteins called amyloid beta (Aβ) and tau.
There is a growing consensus that therapeutic intervention should be initiated at this stage for meaningful disease modification in AD. Thanks to evolving research on biomarkers related to AD pathology, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms.
There is a growing consensus that therapeutic intervention should be initiated at this stage for meaningful disease modification in AD. Thanks to evolving research on biomarkers related to AD pathology, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms.
It's free! Log in now to read
LATEST
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
Advancing Health: ASGCT’s Clinical Trials Spotlight on Cell Therapy and Cell-Based Gene Therapy
2024-05-09
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06